Article Text

Download PDFPDF
Infliximab as a treatment for systemic amyloidosis associated with Crohn’s disease
  1. M Iizuka,
  2. S Konno,
  3. Y Horie,
  4. H Itou,
  5. K Shindo,
  6. S Watanabe
  1. Department of Internal Medicine, Akita University School of Medicine, Akita, Japan
  1. Correspondence to:
    Dr M Iizuka
    Department of Internal Medicine, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; maiizuka{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Systemic AA amyloidosis is a serious and potentially fatal complication of Crohn’s disease.1 This serious complication is associated with approximately 0.9–2.5% of patients with Crohn’s disease but renal failure due to renal amyloidosis is one of the most common causes of death for patients with Crohn’s disease.2 Although drugs such as azathioprine, colchicines, and dimethylsulphoxide are suggested to delay the progression of renal amyloidosis, the efficacy of these drugs on renal amyloidosis has not been fully elucidated.2 Infliximab is a chimeric anti-tumour necrosis factor α (TNF-α) monoclonal antibody. This drug has been proven …

View Full Text


  • Conflict of interest: None declared.

Linked Articles